Verastem Oncology has started a Phase 2 clinical trial evaluating its inhibitors, VS-6766 and defactinib, for the treatment of people with recurrent low-grade serous ovarian cancer (LGSOC), the company announced. The trial seeks to recruit up to 100 female patients — more information is available here — and will investigate the company’s RAF/MEK inhibitor VS-6766, either alone or in combination with defactinib, a FAF inhibitor. “Results to date have demonstrated the clinical activity of VS-6766…
You must be logged in to read/download the full post.
The post Phase 2 Trial Begins Testing VS-6766, Defactinib Combo in Low-grade Serous Ovarian Cancer appeared first on BioNewsFeeds.